PCM
NTLA icon

Penserra Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Penserra Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-6,528
Closed -$206K – 1327
2023
Q3 		$206K Sell
6,528
-105
-2% -$4.07K ﹤0.01% 734
2023
Q2 		$270K Buy
6,633
+273
+4% +$11.1K 0.01% 696
2023
Q1 		$237K Buy
6,360
+740
+13% +$29K ﹤0.01% 659
2022
Q4 		$196K Sell
5,620
-3,152
-36% -$150K ﹤0.01% 697
2022
Q3 		$490K Buy
8,772
+6,656
+315% +$413K 0.01% 435
2022
Q2 		$109K Buy
2,116
+768
+57% +$39K ﹤0.01% 753
2022
Q1 		$97K Buy
+1,348
New +$114K ﹤0.01% 853
2021
Q4 		– Sell
-1,680
Closed -$225K – 1488
2021
Q3 		$225K Buy
1,680
+130
+8% +$19.7K ﹤0.01% 598
2021
Q2 		$250K Buy
1,550
+20
+1% +$1.56K ﹤0.01% 593
2021
Q1 		$122K Buy
1,530
+165
+12% +$11.1K ﹤0.01% 662
2020
Q4 		$74K Buy
1,365
+861
+171% +$31.3K ﹤0.01% 627
2020
Q3 		$10K Buy
+504
New +$10.5K ﹤0.01% 813

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Penserra Capital Management's NTLA Position: Q4 2023 in Review

Penserra Capital Management sold out of Intellia Therapeutics (NTLA) in Q4 2023, closing a stake of 6,528 shares — an estimated $206K sold.

Penserra Capital Management first reported a position in NTLA in Q3 2020 and held it in 12 quarters. The position peaked at $490K in Q3 2022. 292 funds tracked by Wall St. Rank hold NTLA as of Q4 2023.

  • Penserra Capital Management reported no remaining Intellia Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Penserra Capital Management sold 6,528 Intellia Therapeutics shares in Q4 2023, an estimated $206K.
  • Penserra Capital Management first reported a position in Intellia Therapeutics in Q3 2020 and held it in 12 quarters.
  • Penserra Capital Management's Intellia Therapeutics position peaked at $490K in Q3 2022.
  • 292 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2023.

Based on Penserra Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.